Microfluidic Gradient Screen Links Drug Combination Responses to Leukaemia Outcomes

Researchers have developed a microfluidic drug-screening platform, called GradientScreen, that generates overlapping drug gradients on a single device and analyses how two-drug combinations perform in a ratiometric manner, with the aim of guiding personalised treatment for children with acute lymphoblastic leukaemia (ALL). The work, published in Nature Biomedical Engineering, addresses a recognised gap: although molecular and omics-based assays and functional screens are increasingly proposed for high-risk ALL patients, only a few of these approaches are clinically actionable and easily adopted in clinical settings.

The device uses microfluidics to produce overlapping concentration gradients of the drugs being tested, allowing many ratio and dose combinations to be sampled within one assay. The accompanying analysis framework characterises both the efficacy and the synergy of each drug pair as a function of the ratio between the compounds, rather than evaluating doses in isolation. In the reported demonstration, the team applied the platform to a T-ALL cell line and to diagnostic ALL bone marrow aspirate samples, comparing its readouts with a standard well-plate screen.

A central claim of the study is that the platform’s combination response metrics correlate with clinical outcomes under standard paediatric ALL treatment protocols. Using partial least squares regression, the authors report that their metrics correlate with both minimal residual disease (MRD) measured after the initiation of treatment and with later clinical end-points.

The authors also report a second application: evaluating response to experimental therapeutic regimens in patients who did not respond to standard treatment. In such cases, the platform could, according to the study, be used to profile how an individual patient’s leukaemia cells respond to alternative drug combinations outside the standard protocol. The abstract positions the assay as a research-enabling tool for the field, with potential to integrate into clinical pathology workflows to identify difficult-to-treat ALL patients at diagnosis and to screen for alternative treatment strategies at that early stage.

Because the reported findings rest on the correlation of assay metrics with outcome measures through a regression model, the platform's value as a decision-support tool would depend on further validation beyond the correlations reported in the study. The authors themselves frame the system in cautious terms, as an assay that “can serve as a research-enabling tool” with “potential” for clinical integration, rather than as a validated clinical test. Nevertheless, by combining gradient-based microfluidics with ratiometric synergy analysis and a direct link to MRD and later clinical end-points, the study outlines a route by which functional drug-combination screening might move closer to routine use in paediatric precision oncology.

Subject of Research: A microfluidic drug-combination screening platform correlating ratiometric drug synergy metrics with clinical outcomes in paediatric acute lymphoblastic leukaemia.

Article Title: Gradient-driven microfluidic framework for the screening of ratiometric drug combinations towards precision oncology in paediatric leukaemia

Article References: Williams, E. K., Zhang, D. Y., Alese, T. T., Summers, R. J., Musick, J. O., Park, S. I., Tran, R., Kemp, M. L., Porter, C. C., & Lam, W. A. (2026). Gradient-driven microfluidic framework for the screening of ratiometric drug combinations towards precision oncology in paediatric leukaemia. Nature Biomedical Engineering. https://doi.org/10.1038/s41551-026-01818-0

Image Credits: AI Generated

DOI: 10.1038/s41551-026-01818-0

Keywords: acute lymphoblastic leukaemia, microfluidics, drug combination screening, drug synergy, minimal residual disease, precision oncology, partial least squares regression, paediatric leukaemia, functional precision medicine, clinical pathology workflows, Gradient-driven, microfluidic